# A Phase I Clinical Trial Evaluating the Safety, Tolerability, and Pharmacokinetics of CU-40101 Liniment in Single and Multiple Doses in Adult Male Androgenic Alopecia Subjects

> **NCT05380427** · PHASE1 · COMPLETED · sponsor: **Cutia Therapeutics（Wuxi）Co.,Ltd** · enrollment: 80 (actual)

## Conditions studied

- AGA

## Interventions

- **DRUG:** CU-40101

## Key facts

- **NCT ID:** NCT05380427
- **Lead sponsor:** Cutia Therapeutics（Wuxi）Co.,Ltd
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2022-08-15
- **Primary completion:** 2023-11-15
- **Final completion:** 2024-02-22
- **Target enrollment:** 80 (ACTUAL)
- **Last updated:** 2024-09-19


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05380427

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05380427, "A Phase I Clinical Trial Evaluating the Safety, Tolerability, and Pharmacokinetics of CU-40101 Liniment in Single and Multiple Doses in Adult Male Androgenic Alopecia Subjects". Retrieved via AI Analytics 2026-07-20 from https://api.ai-analytics.org/clinical/NCT05380427. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*